Samantha Genardi, PhD. is an experienced immunologist. In her current role at COUR Pharmaceuticals she designs pre-clinical and clinical assays, manages several COUR CNP Platform Products in pipeline development, and drafts regulatory documents for IND submissions. Samantha has been involved in the management of COUR’s pipeline product CNP-104 for the treatment of primary biliary cholangitis from the early concept stage up through IND submission.
Dr. Genardi obtained her doctorate in immunology at Northwestern University. Her doctoral research focused on the role of unconventional T cells (Natural Killer T cells, Mucosal Associated Invariant T cells) in methicillin-resistant Staphylococcus aureus infection. In addition to her immunology training in the lab, she was selected for a clinical collaboration between Northwestern University and the Infectious Disease (ID) department at Lurie Children’s Hospital to immerse Ph.D. candidates in the clinic.
Prior to graduate school, Dr. Genardi worked as a co-op student at Dana Farber Cancer Institute where she characterized knockdown of target genes using shRNA and CRISPR in cancer cell lines. Dr. Genardi also worked as a co-op student at GlaxoSmithKline where she generated and validated DNA oligo libraries to screen drug candidates.
Dr. Genardi has authored manuscripts in several peer-reviewed publications including Frontiers in Immunology, JEM, and PLOS Pathogens and has presented her work at several national research conferences.